Novel Protein Targeted Therapy of Metastatic Melanoma
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2060-2066
Author(s):
Arthur E. Frankel, Han-Mo Koo, Stephen H. Leppla, Nicholas S. Duesbery and George F. Vande Woude
Renaissance of the Biologically Active Vitamin A Derivatives: Established and Novel Directed Therapies for Cancer and Chemoprevention
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2067-2077
Author(s):
J. Brtko and J. Thalhamer
Recent Developments in the Field of Tumor-Inhibiting Metal Complexes
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2078-2089
Author(s):
M. S. Galanski, V. B. Arion, M. A. Jakupec and B. K. Keppler
Gene Regulation in Cancer Gene Therapy Strategies
Journal:
Current Medicinal Chemistry
Volume:
10
Page:
2175-2184
Author(s):
Ian Scanlon, Panos Lehouritis, Ion Niculescu-Duvaz, Richard Marais and Caroline J. Springer
Preface [Hot topic: Tumour-Selective Drug Activation (Executive Editor : L.H. Patterson)]
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
i-i
Author(s):
L. H. Patterson
CB 1954: From the Walker Tumor to NQO2 and VDEPT
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2091-2104
Author(s):
Richard J. Knox, Philip J. Burke, Shiuan Chen and David J. Kerr
Radiogenetic Therapy: Strategies to Overcome Tumor Resistance
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2105-2112
Author(s):
B. Marples, O. Greco, M. C. Joiner and S. D. Scott
Enzyme / Abzyme Prodrug Activation Systems: Potential Use in Clinical Oncology
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2113-2130
Author(s):
Yoshisuke Nishi
Prodrugs in Genetic Chemoradiotherapy
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2131-2154
Author(s):
Adam V. Patterson, Mark P. Saunders and Olga Greco
Enzyme and Proton-Activated Prodrugs for a Selective Cancer Therapy
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2155-2175
Author(s):
L. F. Tietze and T. Feuerstein